Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Immunological biomarkers and TARC/CCL17 in myelodysplastic syndrome: Insights into immune microenvironment regulation

View Full Paper
Ask AI
Bookmark
Share

Authors

PTPınar TığlıoğluAYAsu Fergün Yılmaz

Discussion

Loading...

Member takes

Overview

Analysis shows no significant cytokine differences in MDS patients, highlighting challenges in immune profiling.

Key Points

  • This study aims to investigate the role of immune dysregulation and cytokines in myelodysplastic syndrome (MDS).
  • Analyzed 52 treatment-naive MDS patients and 30 age-matched healthy controls.
  • Quantified serum levels of various cytokines and chemokines using ELISA methodology.
  • Correlated clinical parameters with biomarker profiles using non-parametric testing.
  • No significant differences in cytokines between MDS patients and healthy controls were found.
  • Intermediate-high risk MDS patients exhibited higher blast rates and transfusion requirements.
  • Findings challenge the use of peripheral biomarkers to reflect MDS immune landscape.

Cite This Study

Tığlıoğlu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d508https://doi.org/10.1182/blood-2025-7359
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS2025
  2. 2Bone marrow immune and stromal niche remodeling in myelodysplastic neoplasm patients under erythropoietic therapies by 29-color full-spectrum flow cytometry2025
  3. 3Distinct distributions of lymphocyte subsets in myelodysplastic syndrome correlate with risk stratification2025
  4. 4Interferon-gamma production in the bone marrow of myelodysplastic syndrome patients supports a treg-independent immune-tolerant microenvironment2025
  5. 5Inflammatory profile of lower risk myelodysplastic syndromes2024 · 16 citations